title: Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.
abstract: OBJECTIVE
  This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.
  
  
  RESULTS
  The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.
  
  
  CONCLUSIONS
  Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Icro
authors.initials: I
authors.lastname: Meattini
authors.affiliation: Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
authors.forename: Isacco
authors.initials: I
authors.lastname: Desideri
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Di Cataldo
authors.affiliation: Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
authors.forename: Giulio
authors.initials: G
authors.lastname: Francolini
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: De Luca Cardillo
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Vieri
authors.initials: V
authors.lastname: Scotti
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Loi
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Detti
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.|Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Mangoni
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Benedetta
authors.initials: B
authors.lastname: Agresti
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Baldazzi
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Greto
authors.affiliation: Breast Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: Donato
authors.initials: D
authors.lastname: Casella
authors.affiliation: Breast Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bernini
authors.affiliation: Breast Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: Luis Jose
authors.initials: LJ
authors.lastname: Sanchez
authors.affiliation: Breast Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Orzalesi
authors.affiliation: Senology Radiology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: Jacopo
authors.initials: J
authors.lastname: Nori
authors.affiliation: Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Fambrini
authors.affiliation: Pathology Unit, University of Florence, Florence, Italy.
authors.forename: Simonetta
authors.initials: S
authors.lastname: Bianchi
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.|Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Livi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods; D012449:Safety; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: concomitant radiotherapy; eribulin mesylate; metastatic breast cancer; safety; toxicity